Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice

Oncology Reports

Volumn 35, Issue 3, 2016, Pages 1340-1348

  Zhang, Yu ^a   Xu, Fen ^a   Liang, Hua ^a   Cai, Mengyin ^a   Wen, Xinqiao ^a   Li, Xiaomao ^a   Weng, Jianping ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

AMP activated protein kinase; Apoptosis; Endometrial cancer; Exenatide; Glucagon like peptide 1 analogs

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; CASPASE 3; COMPOUND C; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; UNCLASSIFIED DRUG; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; MTOR PROTEIN, HUMAN; PEPTIDE; RIBONUCLEOTIDE; TARGET OF RAPAMYCIN KINASE; VENOM;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENDOMETRIUM CANCER; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MIDDLE AGED; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH INHIBITION RATE; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; ENDOMETRIAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; PEPTIDES; PHOSPHORYLATION; RIBONUCLEOTIDES; TOR SERINE-THREONINE KINASES; VENOMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955505685     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4476     Document Type: Article

References (39)

1. Barakat RR, Grisby PW and Sabbatini: Corpus: epithelial tumor. In: principles and practice of gynecologic oncology. Hoskin WJ, Perez CA and Young RC (eds). 2nd edition. Lippincott Williams & Wilkins, Philadelphia, PA, pp919-959, 2007.
2. Fader AN, Arriba LN, Frasure HE and von Gruenigen VE: Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 114: 121-127, 2009.
3. von Gruenigen VE, Gil KM, Frasure HE, Jenison EL and Hopkins MP: The impact of obesity and age on quality of life in gynecologic surgery. Am J Obstet Gynecol 193: 1369-1375, 2005.
4. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG and Yee D: Diabetes and cancer: A consensus report. Diabetes Care 33: 1674-1685, 2010.
5. Chia VM, Newcomb PA, Trentham-Dietz A and Hampton JM: Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer 17: 441-446, 2007.
6. Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638, 2003.
7. Pollak M: Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res (Phila) 3: 1060-1065, 2010.
8. Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y and Liao QP: Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 126: 113-120, 2011.
9. Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E and Schwab M: Metformin and cancer: From the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci 34: 126-135, 2013.
10. Smith U and Gale EA: Does diabetes therapy influence the risk of cancer? Diabetologia 52: 1699-1708, 2009.
11. Gallagher EJ and LeRoith D: The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21: 610-618, 2010.
12. Amori RE, Lau J and Pittas AG: Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 298: 194-206, 2007.
13. Bastien-Dionne PO, Valenti L, Kon N, Gu W and Buteau J: Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic cell mass expansion. Diabetes 60: 3217.3222, 2011.
14. Bose AK, Mocanu MM, Carr RD, Brand CL and Yellon DM: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151, 2005.
15. Kimura R, Okouchi M, Fujioka H, Ichiyanagi A, Ryuge F, Mizuno T, Imaeda K, Okayama N, Kamiya Y, Asai K, et al: Glucagon-like peptide-1 (GLP-1) protects against methylglyoxalinduced PC12 cell apoptosis through the PI3K/Akt/mTOR/ GCLc/redox signaling pathway. Neuroscience 162: 1212-1219, 2009.
16. Elashoff M, Matveyenko AV, Gier B, Elashoff R and Butler PC: Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141: 150-156, 2011.
17. Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B and Rubinek T: The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat 132: 449-461, 2012.
18. Koehler JA, Kain T and Drucker DJ: Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology 152: 3362-3372, 2011.
19. Samson SL and Bajaj M: Direct actions of GLP-1 analogues on AMP-activated protein kinase activity are distinct from cyclic AMP accumulation. J Hepatol 58: 634-635, 2013.
20. Xu F, Li Z, Zheng X, Liu H, Liang H, Xu H, Chen Z, Zeng K and Weng J: SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes 63: 3637.3646, 2014.
21. Zhang BB, Zhou G and Li C: AMPK: An emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9: 407-416, 2009.
22. Chen BD, Zhao WC, Jia QA, Zhou WY, Bu Y, Wang ZZ, Wang F, Wu WJ and Wang Q: Effect of the GLP-1 analog exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell line and mouse model. Int J Mol Sci 14: 24293-24304, 2013.
23. Zhao H, Wang L, Wei R, Xiu D, Tao M, Ke J, Liu Y, Yang J, Hong T, Yang J, et al: Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Diabetes Obes Metab 16: 850-860, 2014.
24. Honors MA and Kinzig KP: Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma. Horm Cancer 5: 33-41, 2014.
25. Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Morinaga H, et al: Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes 63: 3891-3905, 2014.
26. Samani AA, Chevet E, Fallavollita L, Galipeau J and Brodt P: Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulinlike growth factor receptor. Cancer Res 64: 3380-3385, 2004.
27. Augustin LS, Dal Maso L, Franceschi S, Talamini R, Polesel J, Kendall CW, Jenkins DJ and Vidgen E: Association between components of the insulin-like growth factor system and endometrial cancer risk. Oncology 67: 54-59, 2004.
28. H irano S, Ito N, Takahashi S and Tamaya T: Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur J Gynaecol Oncol 25: 187-191, 2004.
29. Paveli. J, Radakovi. B and Paveli. K: Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol 105: 727-735, 2007.
30. Shu S, Li X, Yang Y, Zhang Y, Li T, Liang C and Wan J: Inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma. Int Immunopharmacol 11: 244-249, 2011.
31. Navarro M and Baserga R: Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor. Endocrinology 142: 1073-1081, 2001.
32. Schmelzle T and Hall MN: TOR, a central controller of cell growth. Cell 103: 253-262, 2000.
33. Mita MM, Mita A and Rowinsky EK: Mammalian target of rapamycin: A new molecular target for breast cancer. Clin Breast Cancer 4: 126-137, 2003.
34. Feng Z, Zhang H, Levine AJ and Jin S: The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 102: 8204-8209, 2005.
35. Cantley LC and Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245, 1999.
36. H ardie DG: AMPK: A key regulator of energy balance in the single cell and the whole organism. Int J Obes 32 (Suppl 4): S7-S12, 2008.
37. Kahn BB, Alquier T, Carling D and Hardie DG: AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25, 2005.
38. Inoki K, Zhu T and Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590, 2003.
39. Xu WW, Guan MP, Zheng ZJ, Gao F, Zeng YM, Qin Y and Xue YM: Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway. Cell Physiol Biochem 33: 423-432, 2014.